NCT05936970
Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to a DMARD Starting a New bDMARD or tsDMARD Treatment +/- csDMARD
Active, Not Recruiting
Not specifiedAges 18+ObservationalAqtual, Inc.
~1,410 participants
Updated 2026-07-21 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 42 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Clinical Response Prediction
Measured over Approximately 3 months
Conditions
Where it's being run
42 sites across 18 statesFlorida9
California5
Texas5
North Carolina4
Pennsylvania3
Illinois2
New Jersey2
Washington2
Study leadership
- Diana Abdueva · STUDY_DIRECTOR · CEO
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Ability to understand and provide written informed consent.
Male or female ≥18 years of age at enrollment.
Diagnosis of Rheumatoid Arthritis at the time of enrollment.
Prior treatment with at least 1 csDMARD, bDMARD, or tsDMARD
Planning to initiate a new bDMARD (+/- csDMARD) or tsDMARD (+/- csDMARD), within 1 month after enrollment.
Moderate to high Clinical Disease Activity Index (CDAI) of (\>10) with a minimum 4 tender joints and 4 swollen joints at the time of screening.
Exclusion
Unsuitable for participation in the opinion of the principal investigator.
What this trial measures
- Clinical Response PredictionApproximately 3 months
This study aims to identify cfDNA signatures that predict response to specific bDMARD or tsDMARD therapies for RA treatment.